6-氯-2-氟-3-甲基苄胺 | 261762-86-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 6-氯-2-氟-3-甲基苄胺
• 中文别名: 6-氯-2-氟-3-甲基苯甲胺
• 英文名称: 6-chloro-2-fluoro-3-methylbenzylamine
• 英文别名: (6-chloro-2-fluoro-3-methylphenyl)methanamine
• CAS: 261762-86-1
• 化学式: C₈H₉ClFN
• mdl: MFCD01631420
• 分子量: 173.618
• InChiKey: DVMQLADOLJGLSY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  8

反应信息

• 作为反应物：
  描述：

  6-氯-2-氟-3-甲基苄胺 生成 4-(6-chloro-2-fluoro-3-methylbenzyl)-3-(2,3-dichlorophenyl)-4H-1,2,4-triazole
  参考文献：
  名称：

  P2X7 receptor antagonists and methods of use

  摘要：

  这项发明涉及具有化学式(I)或(II)的P2X7拮抗剂化合物，或其药学上可接受的盐、前药、前药的盐或二者的组合，其中R1、R2和R3在规范中有定义。该发明还涉及一种选择性抑制P2X7活性的方法，包括向需要此类治疗的患者施用化合物的治疗有效量，其化学式为(III)、(IV)或(V)，其中R6、R7、R8、R9、R10和R11在规范中有定义。

  公开号：

  US20070105842A1

文献信息

• Biologically active compounds
  申请人：Quibell Martin

  公开号：US20090131502A1

  公开（公告）日：2009-05-21

  The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease and diseases involving matrix or cartilate degradation.

  本发明涉及式(I)的化合物及其药学上可接受的盐。本发明还涉及含有式(I)的化合物的药物组合物，以及将这些化合物用于治疗从骨质疏松症、帕盖特病、查加斯病、疟疾、牙龈疾病、高钙血症、代谢性骨病和涉及基质或软骨降解的疾病中选择的疾病。
• Pyridine and pyrimidine derivatives
  申请人：Davis Martin Jeremy

  公开号：US20050080258A1

  公开（公告）日：2005-04-14

  Compounds of formula (1) are described in which R a and R b is each independently a hydrogen atom or a group R c , or R a and R b together form an oxo (═O) or thio (═S) group; X is a N atom or an optionally substituted CH group: Y is a —O— or —S— atom or —SO— or —SO 2 — group or an optionally substituted —CH 2 — or —NH— group with the proviso that when R a and R b together form an oxo (═O) or thio (═S) group Y is an optionally substituted —CH 2 — or —NH-group; L 1 is a covalent bond or a linker atom or group; p is zero or the integer 1; Alk 1 is an optionally substituted C 1-10 aliphatic or C 1-10 heteroaliphatic chain; n is zero the integer 1, 2 or 3 with the proviso that when n is zero Y is an optionally substituted —CH 2 — group: Ar is an optionally substituted C 6-12 aromatic or C 1-9 heteroaromatic group; m is zero or the integer 1, 2 or 3; q is zero or the integer 1 or 2; R 1 , R c and R d are hydrogen atoms or the substituents described in the patent specification; and the salts, solvates, hydrates and N-oxides thereof. The compounds are potent and selective inhibitors of p38 kinase and are useful in the treatment of immune or inflammatory disorders.

  公式（1）的化合物如下所述：其中Ra和Rb分别独立地是氢原子或基团Rc，或者Ra和Rb共同形成氧（═O）或硫（═S）基团；X是N原子或可选取代的CH基团；Y是—O—或—S—原子或—SO—或—SO2—基团或可选取代的—CH2—或—NH—基团，但当Ra和Rb共同形成氧（═O）或硫（═S）基团时，Y是可选取代的—CH2—或—NH—基团；L1是共价键或连接原子或基团；p为零或整数1；Alk1是可选取代的C1-10脂肪或C1-10杂脂肪链；n为零或整数1、2或3，但当n为零时，Y是可选取代的—CH2—基团；Ar是可选取代的C6-12芳香或C1-9杂芳基团；m为零或整数1、2或3；q为零或整数1或2；R1、Rc和Rd是氢原子或专利说明书中描述的取代基；以及其盐、溶剂化合物、水合物和N-氧化物。这些化合物是p38激酶的有效选择性抑制剂，可用于治疗免疫或炎症性疾病。
• Bicyclic pyrimidine derivatives
  申请人：Arai Hitoshi

  公开号：US20070037834A1

  公开（公告）日：2007-02-15

  [wherein m and n may be the same or different and each represents an integer of 1 to 3 wherein m+n is 4 or less; R 1 represents —NR 4 R 5 (wherein R 4 and R 5 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl or the like); R 2 represents the above Formula (II), Formula (IV) or the like; A represents a single bond, —C(═O)—, —SO 2 —, —OC(═O)— or the like; and R 3 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aralkyl or the like] Bicyclic pyrimidine derivatives represented by the above Formula (I), or quaternary ammonium salts thereof, or pharmaceutically acceptable salts thereof, or the like, are provided. These have anti-inflammatory activities or modulation activities on the functions of TARC and/or MDC and are useful for treating and/or preventing a disease which is related to T cells, such as an allergic disease, an autoimmune disease or transplant rejection.

  提供上述公式（I）所代表的双环嘧啶衍生物，其中m和n可以相同或不同，每个表示1至3的整数，其中m+n小于等于4；R1表示—NR4R5（其中R4和R5可以相同或不同，每个表示氢原子，取代或未取代的低碳基，取代或未取代的芳基烷基或类似物）；R2表示上述公式（II），公式（IV）或类似物；A表示单键，—C（═O）—，—SO2—，—OC（═O）—或类似物；R3表示取代或未取代的低碳基，取代或未取代的环烷基，取代或未取代的芳基烷基或类似物。还提供了上述公式（I）所代表的四元铵盐或药学上可接受的盐或类似物。这些化合物具有抗炎活性或对TARC和/或MDC功能的调节活性，并且用于治疗和/或预防与T细胞相关的疾病，例如过敏性疾病，自身免疫性疾病或移植排斥。
• ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS
  申请人：Pinto Donald J.P.

  公开号：US20110028446A1

  公开（公告）日：2011-02-03

  The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L 1 , M and R 11 are as defined herein. The compounds of Formula (I) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供公式（I）的化合物：或其立体异构体，互变异构体，药学上可接受的盐或溶剂形式，其中变量A，L1，M和R11如本文所定义。公式（I）化合物是凝血级联反应和/或接触激活系统的丝氨酸蛋白酶酶的选择性抑制剂；例如凝血酶，因子Xa，因子XIa，因子IXa，因子VIIa和/或血浆激肽。特别是，涉及到选择性因子XIa抑制剂或fXIa和血浆激肽的双重抑制剂的化合物。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• Tetrahydroquinoline derivatives as P2X7 receptor antagonists
  申请人：RaQualia Pharma Inc.

  公开号：US11077100B2

  公开（公告）日：2021-08-03

  The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.

  本发明涉及本发明的四氢喹啉衍生物或其药学上可接受的盐或其原药、其制备工艺、含有它们的药物组合物以及它们在治疗通过 P2X7 受体介导的各种疾病中的用途。